Alberto Falk Delgado1, Francesca De Luca2, Danielle van Westen3, Anna Falk Delgado4. 1. Department of Surgical sciences, Uppsala University, Uppsala, Sweden. 2. Faculty of Medicine and Surgery, School of Medicine and Health Sciences, University "G. d'Ánnunzio," Chieti, Italy. 3. Image and Function, Skane University Hospital, Lund, Sweden, and Institution for Clinical Sciences Lund, Diagnostic Radiology, Lund University, Lund, Sweden. 4. Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
Abstract
Background: Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods: Cochrane Library, Embase, Medline, and Web of Science Core Collection were searched. Study selection ended November 2017. This study was prospectively registered in PROSPERO (CRD42017080885). Two authors screened all titles and abstracts for possible inclusion. Data were extracted independently by 2 authors. Bivariate random effects meta-analysis was used to describe summary receiver operating characteristics. Trial sequential analysis (TSA) was performed. Results: In total, 15 studies with 505 patients were included. The diagnostic performance of ASL CBF for glioma grading was 0.90 with summary sensitivity 0.89 (0.79-0.90) and specificity 0.80 (0.72-0.89). The diagnostic performance was similar between pulsed ASL (AUC 0.90) with a sensitivity 0.85 (0.71-0.91) and specificity 0.83 (0.69-0.92) and pseudocontinuous ASL (AUC 0.88) with a sensitivity 0.86 (0.79-0.91) and specificity 0.80 (0.65-0.87). In astrocytomas, the diagnostic performance was 0.89 with sensitivity 0.86 (0.79 to 0.91) and specificity 0.79 (0.63 to 0.89). Sensitivity analysis confirmed the robustness of the findings. TSA revealed that the meta-analysis was adequately powered. Conclusion: Arterial spin labeling MR imaging had an excellent diagnostic accuracy for differentiation between high-grade and low-grade glioma. Given its low cost, non-invasiveness, and efficacy, ASL MR imaging should be considered for implementation in the routine workup of patients with glioma.
Background: Arterial spin labeling is an MR imaging technique that measures cerebral blood flow (CBF) non-invasively. The aim of the study is to assess the diagnostic performance of arterial spin labeling (ASL) MR imaging for differentiation between high-grade glioma and low-grade glioma. Methods: Cochrane Library, Embase, Medline, and Web of Science Core Collection were searched. Study selection ended November 2017. This study was prospectively registered in PROSPERO (CRD42017080885). Two authors screened all titles and abstracts for possible inclusion. Data were extracted independently by 2 authors. Bivariate random effects meta-analysis was used to describe summary receiver operating characteristics. Trial sequential analysis (TSA) was performed. Results: In total, 15 studies with 505 patients were included. The diagnostic performance of ASL CBF for glioma grading was 0.90 with summary sensitivity 0.89 (0.79-0.90) and specificity 0.80 (0.72-0.89). The diagnostic performance was similar between pulsed ASL (AUC 0.90) with a sensitivity 0.85 (0.71-0.91) and specificity 0.83 (0.69-0.92) and pseudocontinuous ASL (AUC 0.88) with a sensitivity 0.86 (0.79-0.91) and specificity 0.80 (0.65-0.87). In astrocytomas, the diagnostic performance was 0.89 with sensitivity 0.86 (0.79 to 0.91) and specificity 0.79 (0.63 to 0.89). Sensitivity analysis confirmed the robustness of the findings. TSA revealed that the meta-analysis was adequately powered. Conclusion: Arterial spin labeling MR imaging had an excellent diagnostic accuracy for differentiation between high-grade and low-grade glioma. Given its low cost, non-invasiveness, and efficacy, ASL MR imaging should be considered for implementation in the routine workup of patients with glioma.
Authors: Nicolas R Smoll; Oliver P Gautschi; Bawarjan Schatlo; Karl Schaller; Damien C Weber Journal: Neuro Oncol Date: 2012-07-06 Impact factor: 12.300
Authors: Jennifer S McDonald; Robert J McDonald; Mark E Jentoft; Michael A Paolini; David L Murray; David F Kallmes; Laurence J Eckel Journal: JAMA Pediatr Date: 2017-07-01 Impact factor: 16.193
Authors: R J Jackson; G N Fuller; D Abi-Said; F F Lang; Z L Gokaslan; W M Shi; D M Wildrick; R Sawaya Journal: Neuro Oncol Date: 2001-07 Impact factor: 12.300
Authors: P Lehmann; P Monet; G de Marco; G Saliou; M Perrin; S Stoquart-Elsankari; A Bruniau; J N Vallée Journal: Eur Neurol Date: 2010-06-19 Impact factor: 1.710
Authors: Ke Zhang; Karl-Josef Langen; Irene Neuner; Gabriele Stoffels; Christian Filss; Norbert Galldiks; Lutz Tellmann; Elena Rota Kops; Heinz H Coenen; Hans Herzog; Nadim J Shah Journal: Nucl Med Commun Date: 2014-03 Impact factor: 1.690
Authors: Vittorio Stumpo; Martina Sebök; Christiaan Hendrik Bas van Niftrik; Katharina Seystahl; Nicolin Hainc; Zsolt Kulcsar; Michael Weller; Luca Regli; Jorn Fierstra Journal: MAGMA Date: 2021-12-07 Impact factor: 2.310
Authors: Patricia Clement; Thomas Booth; Fran Borovečki; Kyrre E Emblem; Patrícia Figueiredo; Lydiane Hirschler; Radim Jančálek; Vera C Keil; Camille Maumet; Yelda Özsunar; Cyril Pernet; Jan Petr; Joana Pinto; Marion Smits; Esther A H Warnert Journal: J Med Biol Eng Date: 2020-12-03 Impact factor: 2.213
Authors: Lelio Guida; Vittorio Stumpo; Jacopo Bellomo; Christiaan Hendrik Bas van Niftrik; Martina Sebök; Moncef Berhouma; Andrea Bink; Michael Weller; Zsolt Kulcsar; Luca Regli; Jorn Fierstra Journal: Cancers (Basel) Date: 2022-03-10 Impact factor: 6.639